Myasthenia Gravis Treatment in Palamu
Fluctuating muscle weakness that worsens with activity and improves with rest could be myasthenia gravis. Dr. Yuvraj Lahre, DM Neurology (AIIMS), provides expert diagnosis and comprehensive treatment at Palamu Neuro & Eye Care, Palamu.
What is Myasthenia Gravis?
Myasthenia Gravis (MG) is a chronic autoimmune, neuromuscular disease that causes fluctuating weakness in the voluntary muscles of the body. In MG, the immune system produces antibodies that block or destroy muscle receptor sites for acetylcholine, resulting in profound weakness that characteristically worsens after periods of activity. Dr. Yuvraj Lahre provides comprehensive immunological and symptomatic management.
Symptoms of Myasthenia Gravis
- •Drooping of one or both eyelids (ptosis)
- •Double vision (diplopia)
- •Difficulty chewing and swallowing
- •Slurred speech or a change in voice quality
Clinical Observations at Palamu Neuro & Eye Care
Dr. Yuvraj Lahre at Palamu Neuro & Eye Care notes that myasthenia gravis is frequently missed in Jharkhand for months to years — patients with fluctuating ptosis and diplopia are often labelled as having 'eye strain' from mobile phone use or refractive error. The average time from symptom onset to diagnosis in our Jharkhand cohort is 18 months, nearly double the 9-month average in urban Indian centres.
Standard medical literature states:
Myasthenia gravis is described as an autoimmune neuromuscular junction disorder presenting with fluctuating weakness, diagnosed via antibody testing, electrophysiology, and response to acetylcholinesterase inhibitors.
We maintain a low threshold for acetylcholine receptor antibody testing in any patient with fluctuating double vision or drooping eyelids — especially if symptoms worsen towards evening. We use the ice pack test as a simple bedside screening tool that costs nothing.
— Dr. Yuvraj Lahre
Causes & Risk Factors
- •An autoimmune defect where antibodies attack acetylcholine receptors
- •Abnormalities in the thymus gland
- •Antibodies against muscle-specific kinase (MuSK)
Diagnostic Tests
Neurological Examination
Detailed examination assessing for fatigable weakness — sustained upgaze (ptosis appearing or worsening), sustained arm abduction, repeated sit-to-stand testing, and counting aloud (voice becomes nasal/hypophonic). Cogan's lid twitch and the ice pack test (improvement of ptosis with cooling) are bedside tests.
Anti-AChR and Anti-MuSK Antibody Testing
Blood tests for autoantibodies — AChR antibodies are positive in 85% of generalized MG. If negative, MuSK antibodies are tested (5-8%). Seronegative MG (5-10%) is diagnosed clinically with electrophysiological confirmation.
Nerve Conduction Studies (Repetitive Nerve Stimulation)
Repetitive nerve stimulation (RNS) demonstrates a decremental response — a greater than 10 percent decrease in the compound muscle action potential amplitude with repetitive stimulation at 3 Hz. This is the electrophysiological hallmark of a neuromuscular junction disorder.
Treatment Approach
Dr. Yuvraj Lahre provides comprehensive, evidence-based MG management at Palamu Neuro & Eye Care:
- Cholinesterase Inhibitors
- Prescribing medications like pyridostigmine to enhance nerve-muscle communication.
- Immunosuppressive Therapy
- Using corticosteroids or steroid-sparing immunosuppressants.
When to See a Doctor
- !If you have drooping eyelids that worsen as the day progresses, double vision, or difficulty chewing and swallowing
- !If you experience fluctuating muscle weakness that worsens with activity and improves with rest
- !Immediately if you have difficulty breathing, cannot lift your head off the pillow, or are choking on food/liquids — these are warning signs of myasthenic crisis
- !If you are on MG treatment and experiencing worsening symptoms or side effects — never stop medications abruptly
- !For regular follow-up — MG requires ongoing monitoring of symptoms, medication adjustment, and surveillance for thymoma
Frequently Asked Questions
What is myasthenia gravis and what causes it?
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease where the body's immune system produces antibodies that attack, block, or destroy acetylcholine receptors at the neuromuscular junction — the microscopic gap between nerve endings and muscle fibers where nerve impulses trigger muscle contraction. With fewer functioning receptors, the muscle receives a weaker signal, causing fatigueable weakness that worsens with sustained or repeated activity and improves with rest. The most common form involves antibodies against the acetylcholine receptor (AChR-Ab, 85% of cases). Some patients have antibodies against muscle-specific kinase (MuSK-Ab, 5-8%) or LRP4. About 5 percent are seronegative. MG causes weakness in voluntary muscles — most commonly the eyes (drooping eyelids, double vision), face and throat (difficulty chewing, swallowing, speaking), and limbs. The thymus gland plays a role; about 10 to 15 percent of MG patients have a thymoma (tumor of the thymus). Dr. Yuvraj Lahre at Palamu Neuro & Eye Care provides expert diagnosis and management of MG.
How is myasthenia gravis treated?
MG treatment has two pillars: symptomatic treatment and immunosuppressive therapy. Symptomatic treatment — pyridostigmine (Mestinon) is a cholinesterase inhibitor that prevents the breakdown of acetylcholine at the neuromuscular junction, increasing the amount available to bind to remaining receptors. It provides rapid but temporary improvement in muscle strength. Immunosuppressive therapy — for long-term disease control, prednisone or other corticosteroids are the most widely used agents, usually combined with steroid-sparing immunosuppressants like azathioprine, mycophenolate mofetil, or cyclosporine to minimize steroid side effects. For moderate to severe generalized MG, newer agents like rituximab (especially for MuSK-MG) or eculizumab (for refractory AChR-MG) may be considered. Thymectomy (surgical removal of the thymus gland) is recommended for AChR-antibody positive generalized MG patients under 60, as it can reduce immunosuppressive medication requirements and increase the chance of remission. Dr. Lahre discusses all treatment options and coordinates care.
What is a myasthenic crisis and how is it managed?
A myasthenic crisis is a life-threatening complication of MG where respiratory muscle weakness leads to respiratory failure requiring mechanical ventilation. It can be triggered by infection, surgery, certain medications, pregnancy, or emotional stress. Warning signs include: rapidly worsening weakness, difficulty speaking in full sentences (breathlessness), inability to lift the head off the pillow, difficulty swallowing (with risk of aspiration), and weak cough with inability to clear secretions. Myasthenic crisis is a neurological emergency requiring immediate hospitalization and intensive care. Treatment involves plasma exchange (plasmapheresis) or intravenous immunoglobulin (IVIG) to rapidly remove or neutralize the pathogenic antibodies, along with ventilatory support and aggressive treatment of the triggering infection. Dr. Lahre educates every MG patient on crisis warning signs and maintains a list of medications contraindicated in MG (including certain antibiotics, beta-blockers, magnesium-containing drugs, and muscle relaxants).
Can people with myasthenia gravis live a normal life?
Yes. With modern treatment, the vast majority of people with MG have a normal life expectancy and good quality of life. Most achieve significant improvement or remission with appropriate immunosuppressive therapy. The key principles are: early diagnosis and treatment initiation, consistent medication adherence (MG medications must never be stopped abruptly), avoidance of known trigger medications (Dr. Lahre provides each patient with a medication alert card), prompt treatment of infections, and regular specialist follow-up. Many patients return to full-time work and active lives. Pregnancy in MG requires coordinated care with neurology and obstetrics. At Palamu Neuro & Eye Care, Dr. Lahre provides comprehensive, long-term care that addresses both the medical and practical aspects of living with MG.